AU2010329762B2 - Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same - Google Patents

Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same Download PDF

Info

Publication number
AU2010329762B2
AU2010329762B2 AU2010329762A AU2010329762A AU2010329762B2 AU 2010329762 B2 AU2010329762 B2 AU 2010329762B2 AU 2010329762 A AU2010329762 A AU 2010329762A AU 2010329762 A AU2010329762 A AU 2010329762A AU 2010329762 B2 AU2010329762 B2 AU 2010329762B2
Authority
AU
Australia
Prior art keywords
formula
compound
group
alk
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010329762A
Other languages
English (en)
Other versions
AU2010329762A1 (en
Inventor
Patrick Casara
Anne-Marie Chollet
Alain Dhainaut
Jean-Michel Henlin
Pierre Lestage
Fany Panayi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42711699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010329762(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2010329762A1 publication Critical patent/AU2010329762A1/en
Application granted granted Critical
Publication of AU2010329762B2 publication Critical patent/AU2010329762B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010329762A 2009-12-09 2010-12-08 Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same Ceased AU2010329762B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR09.05953 2009-12-09
FR0905953A FR2953521B1 (fr) 2009-12-09 2009-12-09 Nouveaux derives azabicyclo[3.1.0]hex-2-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2010/000823 WO2011070253A1 (fr) 2009-12-09 2010-12-08 Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
AU2010329762A1 AU2010329762A1 (en) 2012-06-21
AU2010329762B2 true AU2010329762B2 (en) 2013-10-03

Family

ID=42711699

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010329762A Ceased AU2010329762B2 (en) 2009-12-09 2010-12-08 Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same

Country Status (32)

Country Link
US (1) US20120283245A1 (enExample)
EP (1) EP2509947A1 (enExample)
JP (1) JP2013513589A (enExample)
KR (1) KR20120102763A (enExample)
CN (1) CN102652127A (enExample)
AP (1) AP2012006352A0 (enExample)
AR (1) AR079265A1 (enExample)
AU (1) AU2010329762B2 (enExample)
BR (1) BR112012013666A2 (enExample)
CA (1) CA2782469C (enExample)
CL (1) CL2012001479A1 (enExample)
CO (1) CO6541535A2 (enExample)
CR (1) CR20120286A (enExample)
CU (1) CU20120091A7 (enExample)
EA (1) EA201200849A1 (enExample)
EC (1) ECSP12011950A (enExample)
FR (1) FR2953521B1 (enExample)
GE (1) GEP20156227B (enExample)
IN (1) IN2012DN04966A (enExample)
MA (1) MA33882B1 (enExample)
MX (1) MX2012006578A (enExample)
NI (1) NI201200099A (enExample)
PE (1) PE20121475A1 (enExample)
PH (1) PH12012501053A1 (enExample)
SA (1) SA110320011B1 (enExample)
SG (1) SG181082A1 (enExample)
TN (1) TN2012000267A1 (enExample)
TW (1) TW201200499A (enExample)
UA (1) UA102950C2 (enExample)
UY (1) UY33072A (enExample)
WO (1) WO2011070253A1 (enExample)
ZA (1) ZA201203943B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529307A (ja) * 2013-09-09 2016-09-23 サノフイ アルツハイマー病の処置に使用するためのｈ３受容体アンタゴニスト

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089747A1 (fr) * 2004-02-20 2005-09-29 Les Laboratoires Servier Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006136223A1 (en) * 2005-04-15 2006-12-28 Glaxo Group Limited Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
WO2007063000A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089747A1 (fr) * 2004-02-20 2005-09-29 Les Laboratoires Servier Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006136223A1 (en) * 2005-04-15 2006-12-28 Glaxo Group Limited Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
WO2007063000A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives

Also Published As

Publication number Publication date
WO2011070253A8 (fr) 2012-08-02
EP2509947A1 (fr) 2012-10-17
SG181082A1 (en) 2012-07-30
CA2782469C (fr) 2014-04-08
AU2010329762A1 (en) 2012-06-21
ECSP12011950A (es) 2012-07-31
WO2011070253A1 (fr) 2011-06-16
AP2012006352A0 (en) 2012-08-31
IN2012DN04966A (enExample) 2015-09-25
JP2013513589A (ja) 2013-04-22
GEP20156227B (en) 2015-01-26
EA201200849A1 (ru) 2013-01-30
CU20120091A7 (es) 2012-07-31
CN102652127A (zh) 2012-08-29
BR112012013666A2 (pt) 2016-04-19
CL2012001479A1 (es) 2013-02-08
FR2953521A1 (fr) 2011-06-10
ZA201203943B (en) 2013-08-28
AR079265A1 (es) 2012-01-04
US20120283245A1 (en) 2012-11-08
TN2012000267A1 (fr) 2013-12-12
CR20120286A (es) 2012-08-20
FR2953521B1 (fr) 2011-11-18
TW201200499A (en) 2012-01-01
PH12012501053A1 (en) 2013-02-04
UA102950C2 (ru) 2013-08-27
SA110320011B1 (ar) 2013-10-01
CO6541535A2 (es) 2012-10-16
MX2012006578A (es) 2012-06-25
PE20121475A1 (es) 2012-10-20
NI201200099A (es) 2012-11-09
CA2782469A1 (fr) 2011-06-16
KR20120102763A (ko) 2012-09-18
MA33882B1 (fr) 2013-01-02
UY33072A (es) 2011-05-31

Similar Documents

Publication Publication Date Title
AU2002345266B2 (en) 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7446123B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists
AU2010329762B2 (en) Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same
ZA200903939B (en) Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them
TW201144280A (en) New compounds of the hexahydrocyclopenta[b]pyrrole type, a process for their preparation and pharmaceutical compositions containing them
HK1175460A (en) Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same
ZA201008651B (en) Azabicyclo[3.2.0]hept-3-yl compounds,a process for their preparation and pharmaceutical compositions containing them
HK1139679A (zh) 新的氮杂双环化合物、它们的制备方法以及含有它们的药用组合物
TW201144279A (en) New azabicyclo[3.2.0]hept-6-yl compounds, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CASARA, PATRICK; CHOLLET, ANNE-MARIE; DHAINAUT, ALAIN; HENLIN, JEAN-MICHEL; LESTAGE, PIERRE AND PANAYI, FANY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired